Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Reduced replication fork speed promotes pancreatic endocrine differentiation and controls graft size
Lina Sui, Yurong Xin, Qian Du, Daniela Georgieva, Giacomo Diedenhofen, Leena Haataja, Qi Su, Michael V. Zuccaro, Jinrang Kim, Jiayu Fu, Yuan Xing, Yi He, Danielle Baum, Robin S. Goland, Yong Wang, Jose Oberholzer, Fabrizio Barbetti, Peter Arvan, Sandra Kleiner, Dieter Egli
Lina Sui, Yurong Xin, Qian Du, Daniela Georgieva, Giacomo Diedenhofen, Leena Haataja, Qi Su, Michael V. Zuccaro, Jinrang Kim, Jiayu Fu, Yuan Xing, Yi He, Danielle Baum, Robin S. Goland, Yong Wang, Jose Oberholzer, Fabrizio Barbetti, Peter Arvan, Sandra Kleiner, Dieter Egli
View: Text | PDF
Research Article Cell biology Stem cells

Reduced replication fork speed promotes pancreatic endocrine differentiation and controls graft size

  • Text
  • PDF
Abstract

Limitations in cell proliferation are important for normal function of differentiated tissues and essential for the safety of cell replacement products made from pluripotent stem cells, which have unlimited proliferative potential. To evaluate whether these limitations can be established pharmacologically, we exposed pancreatic progenitors differentiating from human pluripotent stem cells to small molecules that interfere with cell cycle progression either by inducing G1 arrest or by impairing S phase entry or S phase completion and determined growth potential, differentiation, and function of insulin-producing endocrine cells. We found that the combination of G1 arrest with a compromised ability to complete DNA replication promoted the differentiation of pancreatic progenitor cells toward insulin-producing cells and could substitute for endocrine differentiation factors. Reduced replication fork speed during differentiation improved the stability of insulin expression, and the resulting cells protected mice from diabetes without the formation of cystic growths. The proliferative potential of grafts was proportional to the reduction of replication fork speed during pancreatic differentiation. Therefore, a compromised ability to enter and complete S phase is a functionally important property of pancreatic endocrine differentiation, can be achieved by reducing replication fork speed, and is an important determinant of cell-intrinsic limitations of growth.

Authors

Lina Sui, Yurong Xin, Qian Du, Daniela Georgieva, Giacomo Diedenhofen, Leena Haataja, Qi Su, Michael V. Zuccaro, Jinrang Kim, Jiayu Fu, Yuan Xing, Yi He, Danielle Baum, Robin S. Goland, Yong Wang, Jose Oberholzer, Fabrizio Barbetti, Peter Arvan, Sandra Kleiner, Dieter Egli

×

Figure 7

Mice transplanted with cells pretreated with APH secrete high human C-peptide and are protected from induced diabetes.

Options: View larger image (or click on image) Download as PowerPoint
Mice transplanted with cells pretreated with APH secrete high human C-pe...
(A) Human C-peptide serum concentration in mice at different time points after transplantation with cells treated with APH (APH) and control cells (MEL1) at fed state. (B) Human C-peptide serum concentration in mice at 12–14 weeks after transplantation with APH cells (APH) and control cells (MEL1) at fed state, fasting, and 30 minutes after glucose injection. Two-way ANOVA *P < 0.05; ****P < 0.0001. (C) Blood glucose levels of STZ-treated mice without transplantation (No Tx) (P = 2), transplanted with control cells (Tx-Control) (n = 2), and with APH-treated cells (Tx-APH) (n = 6). Blood glucose levels of Tx-Control and No Tx mice were monitored until persistent hyperglycemia required euthanasia according to animal protocol. (D) Glucose tolerance test of STZ-treated mice in fed state, fasting state, and 15–120 minutes after glucose injection. Intraperitoneal glucose tolerance test (IPGTT) was performed on day 14 after STZ treatment. (E) Area under the curve of glucose tolerance test was calculated to compare among Tx-Control, Tx-APH, and No Tx. (F) Serum human insulin concentrations of STZ-treated mice transplanted with APH-treated cells at fed state, fasting, and 30 minutes after glucose injection.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts